View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Eventse-therapeutics 배당 및 자사주 매입배당 기준 점검 0/6e-therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.06%자사주 매입 수익률총 주주 수익률-0.06%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 07e-therapeutics plc Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHe-therapeutics plc announced it will present new preclinical results on its GalOmic small-interfering RNA (siRNA) candidate ETX-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025. In the leading Gubra-Amylin NASH diet-induced obese (GAN-DIO) mouse model, ETX-312 demonstrated: Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP-1/GIP receptor agonist or an FGF-21 analogue. All mice receiving combination therapy achieved 2-point reductions in NAS, with improvements of up to 5 points observed. Slowed fibrosis progression comparable to that achieved with GLP-1/G IP receptor agonist or FGF-21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and in circulating biomarkers TIMP-1 and PIIINP. ETX-312 is currently in IND-enabling studies, and the Company remains on track to submit a regulatory submission by the end of 2025.공시 • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.공시 • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdom공시 • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.공시 • Oct 20e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023공시 • Sep 21E-Therapeutics plc Announces Senior Management Updatee-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.공시 • May 11e-therapeutics plc, Annual General Meeting, Jul 18, 2023e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ETXP.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ETXP.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장e-therapeutics 배당 수익률 vs 시장ETXP.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ETXP.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.4%분석가 예측 (ETXP.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ETXP.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ETXP.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ETXP.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ETXP.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/07/14 10:10종가2024/04/16 00:00수익2024/01/31연간 수익2024/01/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스e-therapeutics plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 07e-therapeutics plc Presents New Data Supporting ETX-312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASHe-therapeutics plc announced it will present new preclinical results on its GalOmic small-interfering RNA (siRNA) candidate ETX-312 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) at the European Association for the Study of the Liver (EASL) Congress, 7th-10th May 2025. In the leading Gubra-Amylin NASH diet-induced obese (GAN-DIO) mouse model, ETX-312 demonstrated: Dramatic improvements in NAFLD Activity Score (NAS) when administered as monotherapy or in combination with a GLP-1/GIP receptor agonist or an FGF-21 analogue. All mice receiving combination therapy achieved 2-point reductions in NAS, with improvements of up to 5 points observed. Slowed fibrosis progression comparable to that achieved with GLP-1/G IP receptor agonist or FGF-21 analogue controls, supported by statistically significant reductions in hepatic collagen staining and in circulating biomarkers TIMP-1 and PIIINP. ETX-312 is currently in IND-enabling studies, and the Company remains on track to submit a regulatory submission by the end of 2025.
공시 • Apr 11e-therapeutics plc Considers Switching Its Listing to New YorkShares of e-therapeutics plc fell 12% after the company said it is considering switching its listing to New York, a move that would deal a further blow to the London bourse following a spate of defections in recent months. The provider of digital technology for drug discovery also said April 10, 2024 that it raised GBP 28.9 million ($36.6 million) via a high-premium share subscription by its two largest shareholders. Shares at 0752 GMT were down 1.50 pence at 11.0 pence. They are currently down 25% over the past 12 months. e-Therapeutics is seeking shareholder approval to cancel its current listing on London's junior AIM, saying it doesn't believe it accurately reflects its value and is a hindrance to its plans given a significant reduction in liquidity and access to capital. It also said it believes a listing on U.S. Nasdaq will provide a higher valuation, but cautioned that there is no certainty the listing will be achievable in any given time frame. The London delisting plan has the support of shareholders owing 46.68% of its shares, it said. e-Therapeutics has called a general meeting for April 29 to seek approval to delist its shares, and if approved, expects cancellation to become effective from May 9.
공시 • Apr 10e-therapeutics plc, Annual General Meeting, Apr 29, 2024e-therapeutics plc, Annual General Meeting, Apr 29, 2024, at 11:30 Coordinated Universal Time. Location: Unit 4B, Floor 4, 4 Kingdom Street, Paddington Central London United Kingdom
공시 • Dec 27e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United Statese-therapeutics plc announced that, with effect from 31 December 2023, its ordinary shares ("Ordinary Shares") will cease to trade on the OTCQX Best Market in the United States ("OTCQX"). The Company's Ordinary Shares began trading on OTCQX on 24 September 2021, but there has been limited trading since that date. As such, the expenses associated with the Company's Ordinary Shares trading on OTCQX outweigh the benefits for e-therapeutics shareholders. The Ordinary Shares will continue to be admitted to trading on AIM as the Company's primary market.
공시 • Oct 20e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023e-therapeutics plc announced that they will report first half, 2024 results on Oct 26, 2023
공시 • Sep 21E-Therapeutics plc Announces Senior Management Updatee-therapeutics plc announces that Michael Bretherton has stepped down from his role as interim CFO and will now focus on his role as a Non-Executive Director of the Company. Timothy Bretherton, Director of Finance and Operations, will assume the CFO role (non-board) with immediate effect. Timothy is an experienced finance leader having held multiple senior roles prior to joining e-therapeutics in May 2022. He has a strong practical background previously gained over 12 years in operational and finance roles including four years as a consultant at PwC and three years as an auditor at Mazars. He has a degree in Economics from the University of Leicester and is a member of the Institute of Chartered Accountants in England and Wales.
공시 • May 11e-therapeutics plc, Annual General Meeting, Jul 18, 2023e-therapeutics plc, Annual General Meeting, Jul 18, 2023, at 11:30 Coordinated Universal Time. Location: 4 Kingdom Street Paddington, London W2 6BD London United Kingdom Agenda: To receive the accounts for the financial year ended 31 January 2023 together with the Directors' Report and the Auditor's Report for that period; to re-elect Ali Mortazavi as a Director of the Company, who has been a Director since 10 February 2020 and was last re-elected by shareholders in March 2020; to re-appoint Crowe U.K. LLP as the Auditor of the Company; to authorise the Directors to set the remuneration of the Auditor of the Company; and to consider other matters.